Q32 Bio (FIXX) Stock Forecast, Price Target & Predictions
FIXX Stock Forecast
Q32 Bio stock forecast is as follows: an average price target of $2.70 (represents a 188.86% upside from FIXX’s last price of $0.93) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
FIXX Price Target
The average price target for Q32 Bio (FIXX) is $2.70 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $2.70 to $2.70. This represents a potential 188.86% upside from FIXX's last price of $0.93.
FIXX Analyst Ratings
According to 4 Wall Street analysts, Q32 Bio's rating consensus is 'Buy'. The analyst rating breakdown for FIXX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Q32 Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 28, 2022 | - | Credit Suisse | $2.70 | $1.61 | 67.70% | 188.86% |
The latest Q32 Bio stock forecast, released on Apr 28, 2022 by Credit Suisse company, set a price target of $2.70, which represents a 67.70% increase from the stock price at the time of the forecast ($1.61), and a 188.86% increase from FIXX last price ($0.93).
Q32 Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.93 | $0.93 | $0.93 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Q32 Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Q32 Bio's last price of $0.93. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 28, 2022 | Credit Suisse | - | Neutral | Initialise |
| Feb 22, 2022 | Chardan Capital | Buy | Buy | Hold |
| Feb 22, 2022 | BTIG | Buy | Buy | Hold |
| Feb 22, 2022 | RBC Capital | - | Sector Perform | Downgrade |
| Feb 22, 2022 | Oppenheimer | - | Perform | Downgrade |
Q32 Bio's last stock rating was published by Credit Suisse on Apr 28, 2022. The company Initialise its FIXX rating from "null" to "Neutral".
Q32 Bio Financial Forecast
Q32 Bio Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $802.00K | $802.00K | - | - | $802.00K | $802.00K | - | - | $29.30M | $980.00K | - | - | $588.00K | $563.00K | - | - | $270.00K | $823.37K |
| Avg Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $830.50K | $1.01M | $830.60K | $860.60K | $1.00M | $7.21M | $853.00K | $643.70K | $429.70K | $576.86K | $1.22M | $573.00K | $491.14K | $580.00K | $1.37M | $490.00K | $800.00K | $975.00K | $729.71K |
| High Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $830.50K | $1.01M | $830.60K | $860.60K | $1.00M | $7.21M | $853.00K | $643.70K | $429.70K | $576.86K | $1.22M | $573.00K | $491.14K | $580.00K | $1.37M | $490.00K | $800.00K | $975.00K | $875.65K |
| Low Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $830.50K | $1.01M | $830.60K | $860.60K | $1.00M | $7.21M | $853.00K | $643.70K | $429.70K | $576.86K | $1.22M | $573.00K | $491.14K | $580.00K | $1.37M | $490.00K | $800.00K | $975.00K | $583.76K |
| # Analysts | 1 | 1 | 1 | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 |
| Surprise % | - | - | - | - | - | - | - | 0.79% | 0.97% | - | - | 0.11% | 0.94% | - | - | 50.80% | 0.80% | - | - | 1.01% | 0.41% | - | - | 0.28% | 1.13% |
Q32 Bio's average Quarter revenue forecast for Jul 23 based on 0 analysts is $830.50K, with a low forecast of $830.50K, and a high forecast of $830.50K. FIXX's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $802.00K (Mar 23).
Q32 Bio EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 |
| EBITDA | - | - | - | - | - | - | - | $-27.29M | $-34.20M | - | - | $-168.52M | $-31.51M | - | - | $1.01M | $-27.73M | - | - | $-33.20M | $-22.45M | - | - | $-22.59M | $-10.30M |
| Avg Forecast | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-830.50K | $-1.01M | $-830.60K | $-29.32M | $-1.00M | $-7.21M | $-853.00K | $-643.70K | $-429.70K | $-576.86K | $-1.22M | $-573.00K | $-491.14K | $-28.32M | $-1.37M | $-490.00K | $-800.00K | $-17.90M | $-9.13M |
| High Forecast | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-830.50K | $-1.01M | $-830.60K | $-23.46M | $-1.00M | $-7.21M | $-853.00K | $-643.70K | $-429.70K | $-576.86K | $-1.22M | $-573.00K | $-491.14K | $-22.66M | $-1.37M | $-490.00K | $-800.00K | $-14.32M | $-7.30M |
| Low Forecast | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-830.50K | $-1.01M | $-830.60K | $-35.19M | $-1.00M | $-7.21M | $-853.00K | $-643.70K | $-429.70K | $-576.86K | $-1.22M | $-573.00K | $-491.14K | $-33.98M | $-1.37M | $-490.00K | $-800.00K | $-21.48M | $-10.96M |
| Surprise % | - | - | - | - | - | - | - | 26.89% | 41.17% | - | - | 23.38% | 36.94% | - | - | -1.75% | 22.71% | - | - | 1.17% | 16.43% | - | - | 1.26% | 1.13% |
0 analysts predict FIXX's average Quarter EBITDA for Jul 21 to be $-429.70K, with a high of $-429.70K and a low of $-429.70K. This is -142.67% lower than Q32 Bio's previous annual EBITDA (Mar 21) of $1.01M.
Q32 Bio Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 |
| Net Income | - | - | - | - | - | - | - | $-28.84M | $-32.94M | - | - | $92.11M | $-33.58M | - | - | $-1.07M | $-29.79M | - | - | $-35.33M | $-24.17M | - | - | $-23.85M | $-10.52M |
| Avg Forecast | $-326.79K | $-350.13K | $-396.81K | $-536.86K | $-700.25K | $-980.36K | $-1.10M | $-1.24M | $-1.15M | $-31.48M | $-1.25M | $542.37M | $-1.34M | $-1.37M | $-1.34M | $-1.90M | $-1.54M | $-1.89M | $-1.73M | $-30.14M | $-1.59M | $-1.40M | $-1.28M | $-18.90M | $-9.33M |
| High Forecast | $-326.79K | $-350.13K | $-396.81K | $-536.86K | $-700.25K | $-980.36K | $-1.10M | $-1.24M | $-1.15M | $-25.18M | $-1.25M | $650.84M | $-1.34M | $-1.37M | $-1.34M | $-1.52M | $-1.54M | $-1.89M | $-1.73M | $-24.11M | $-1.59M | $-1.40M | $-1.28M | $-15.12M | $-7.46M |
| Low Forecast | $-326.79K | $-350.13K | $-396.81K | $-536.86K | $-700.25K | $-980.36K | $-1.10M | $-1.24M | $-1.15M | $-37.78M | $-1.25M | $433.89M | $-1.34M | $-1.37M | $-1.34M | $-2.28M | $-1.54M | $-1.89M | $-1.73M | $-36.16M | $-1.59M | $-1.40M | $-1.28M | $-22.68M | $-11.19M |
| Surprise % | - | - | - | - | - | - | - | 23.32% | 28.67% | - | - | 0.17% | 25.05% | - | - | 0.56% | 19.37% | - | - | 1.17% | 15.16% | - | - | 1.26% | 1.13% |
Q32 Bio's average Quarter net income forecast for Jul 22 is $-1.25M, with a range of $-1.25M to $-1.25M. FIXX's average Quarter net income forecast represents a -101.36% decrease compared to the company's last Quarter net income of $92.11M (Mar 22).
Q32 Bio SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 |
| SG&A | - | - | - | - | - | - | - | $8.32M | $8.15M | - | - | $14.15M | $10.78M | - | - | $8.66M | $7.59M | - | - | $7.77M | $5.78M | - | - | $4.86M | $3.83M |
| Avg Forecast | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $10.78M | $13.17M | $10.78M | $11.17M | $12.99M | $93.55M | $11.07M | $8.35M | $5.58M | $7.49M | $15.85M | $7.44M | $6.37M | $7.53M | $17.74M | $6.36M | $10.38M | $12.66M | $9.47M |
| High Forecast | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $10.78M | $13.17M | $10.78M | $11.17M | $12.99M | $93.55M | $11.07M | $8.35M | $5.58M | $7.49M | $15.85M | $7.44M | $6.37M | $7.53M | $17.74M | $6.36M | $10.38M | $12.66M | $11.37M |
| Low Forecast | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $6.49M | $10.78M | $13.17M | $10.78M | $11.17M | $12.99M | $93.55M | $11.07M | $8.35M | $5.58M | $7.49M | $15.85M | $7.44M | $6.37M | $7.53M | $17.74M | $6.36M | $10.38M | $12.66M | $7.58M |
| Surprise % | - | - | - | - | - | - | - | 0.63% | 0.76% | - | - | 0.15% | 0.97% | - | - | 1.16% | 0.48% | - | - | 1.03% | 0.33% | - | - | 0.38% | 0.40% |
Q32 Bio's average Quarter SG&A projection for Jul 23 is $10.78M, based on 0 Wall Street analysts, with a range of $10.78M to $10.78M. The forecast indicates a 29.48% rise compared to FIXX last annual SG&A of $8.32M (Mar 23).
Q32 Bio EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | - | - | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 |
| EPS | - | - | - | - | - | - | - | $-0.50 | $-0.57 | - | - | $1.61 | $-0.59 | - | - | $-0.02 | $-0.66 | - | - | $-0.78 | $-0.54 | - | - | $-0.64 | $-4.21 |
| Avg Forecast | $-0.14 | $-0.15 | $-0.17 | $-0.23 | $-0.30 | $-0.42 | $-0.47 | $-0.53 | $-0.49 | $-0.46 | $-0.54 | $-0.49 | $-0.57 | $-0.59 | $-0.57 | $-0.61 | $-0.66 | $-0.81 | $-0.74 | $-0.69 | $-0.68 | $-0.60 | $-0.55 | $-0.54 | $-3.35 |
| High Forecast | $-0.14 | $-0.15 | $-0.17 | $-0.23 | $-0.30 | $-0.42 | $-0.47 | $-0.53 | $-0.49 | $-0.46 | $-0.54 | $-0.49 | $-0.57 | $-0.59 | $-0.57 | $-0.61 | $-0.66 | $-0.81 | $-0.74 | $-0.69 | $-0.68 | $-0.60 | $-0.55 | $-0.54 | $-2.68 |
| Low Forecast | $-0.14 | $-0.15 | $-0.17 | $-0.23 | $-0.30 | $-0.42 | $-0.47 | $-0.53 | $-0.49 | $-0.46 | $-0.54 | $-0.49 | $-0.57 | $-0.59 | $-0.57 | $-0.61 | $-0.66 | $-0.81 | $-0.74 | $-0.69 | $-0.68 | $-0.60 | $-0.55 | $-0.54 | $-4.02 |
| Surprise % | - | - | - | - | - | - | - | 0.94% | 1.16% | - | - | -3.27% | 1.03% | - | - | 0.03% | 1.00% | - | - | 1.13% | 0.78% | - | - | 1.19% | 1.26% |
According to 0 Wall Street analysts, Q32 Bio's projected average Quarter EPS for Jul 22 is $-0.54, with a low estimate of $-0.54 and a high estimate of $-0.54. This represents a -133.39% decrease compared to FIXX previous annual EPS of $1.61 (Mar 22).
Q32 Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.25 | $44.57 | 174.28% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
FIXX Forecast FAQ
Is Q32 Bio a good buy?
Yes, according to 4 Wall Street analysts, Q32 Bio (FIXX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of FIXX's total ratings.
What is FIXX's price target?
Q32 Bio (FIXX) average price target is $2.7 with a range of $2.7 to $2.7, implying a 188.86% from its last price of $0.935. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Q32 Bio stock go up soon?
According to Wall Street analysts' prediction for FIXX stock, the company can go up by 188.86% (from the last price of $0.935 to the average price target of $2.7), up by 188.86% based on the highest stock price target, and up by 188.86% based on the lowest stock price target.
Can Q32 Bio stock reach $1?
FIXX's average twelve months analyst stock price target of $2.7 supports the claim that Q32 Bio can reach $1 in the near future.
What are Q32 Bio's analysts' financial forecasts?
FIXX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2M (high $2M, low $2M), average EBITDA is $-2M (high $-2M, low $-2M), average net income is $-1.611M (high $-1.611M, low $-1.611M), average SG&A $25.96M (high $25.96M, low $25.96M), and average EPS is $-0.69 (high $-0.69, low $-0.69).
Did the FIXX's actual financial results beat the analysts' financial forecasts?
Based on Q32 Bio's last annual report (Dec 2023), the company's revenue was $1.16M, which missed the average analysts forecast of $2.85M by -59.37%. Apple's EBITDA was $-101M, beating the average prediction of $-2.845M by 3465.08%. The company's net income was $-113M, beating the average estimation of $-4.021M by 2709.54%. Apple's SG&A was $31.26M, missing the average forecast of $36.93M by -15.36%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-1.722 by -99.88%. In terms of the last quarterly report (Mar 2023), Q32 Bio's revenue was $802K, missing the average analysts' forecast of $1.01M by -20.95%. The company's EBITDA was $-27.286M, beating the average prediction of $-1.015M by 2589.42%. Q32 Bio's net income was $-28.844M, beating the average estimation of $-1.237M by 2231.55%. The company's SG&A was $8.32M, missing the average forecast of $13.17M by -36.78%. Lastly, the company's EPS was $-0.5, missing the average prediction of $-0.53 by -5.66%